

## Egypt achieves self-sufficiency in plasma-derived medicines thanks to Grifols

- *The company, through Grifols Egypt for Plasma Derivatives (GEPD), has achieved clinical self-sufficiency in immunoglobulins, albumin, and coagulation factors for bleeding disorders*
- *Grifols, through GEPD, will contribute c. 55 million euros to Egypt's GDP in 2025 alone, and estimates that it will contribute more than 272 million euros yearly to the country's GDP by 2030*
- *The company has already created 1,200 high-quality, highly skilled direct jobs and more than 14,000 indirect jobs in Egypt and estimates it will generate over 180,000 new jobs annually in the country, 44,000 direct, 107,000 indirect, and 34,000 induced*
- *Egypt is the sixth country worldwide to achieve plasma self-sufficiency*

**Barcelona, Spain, December 4, 2025** - Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, has achieved clinical self-sufficiency in Egypt for three essential plasma-derived medications: immunoglobulins, albumin, and coagulation factors for bleeding disorders, through Grifols Egypt for Plasma Derivatives (GEPD). Egypt is the sixth country worldwide to achieve plasma self-sufficiency. This milestone comes five years after Grifols and the Egyptian government signed an alliance in 2020 to deploy the country's, and the broader Africa and Middle East regions, first comprehensive plasma ecosystem, with a joint investment of 280 million euros.

Grifols, through GEPD, ensures a regular and sustained distribution of medicines produced from Egyptian plasma to public hospitals and health centers, guaranteeing coverage for patients with chronic or rare diseases without relying on the international market. This is the first time that Egypt has supplied itself self-sufficiently with medicines derived from national plasma, after decades in which the country depended almost entirely on imported plasma—mainly from the United States—which represented a structural healthcare vulnerability that the Egyptian government had identified as a national strategic priority.

The company continues working to consolidate in Egypt the entire value chain for the manufacturing of medicines derived from national plasma within the country itself, and to guarantee long-term supply for the entire Egyptian population. Grifols currently has 16 donation centers in Egypt, with four additional centers to be added in 2026. It also has an analysis laboratory and a comprehensive plasma logistics center that ensures maximum traceability and control throughout the entire value chain, as has been the case in all of Grifols' operations since 1971. In addition, Grifols is completing the construction of a plasma processing plant in Egypt, whose first phase will be operational in 2026. The donation centers have passed inspections by the PPTA and European authorities to ensure compliance with the highest safety and quality standards in all processes.

**Tomás Dagá**, Grifols' board member and Vice President of GEPD, said: "Plasma self-sufficiency in Egypt marks a turning point for the country's public health. Turning a national strategic goal into a tangible reality is an achievement that combines scientific innovation and commitment. Egypt is a key market for Grifols, its scale and position in the region make it a strategic hub. At Grifols, we are proud to have helped Egypt ensure safe and sustainable access to these medicines for its citizens, and we are working to make this model an example for other countries seeking to guarantee safe and sustainable access to essential plasma therapies."

Recently, Grifols appointed Tomás Dagá Vice Chairman of the board of Grifols Egypt for Plasma Derivatives (GEPD), strengthening the alliance and strategic leadership of a key project for Egypt's healthcare self-sufficiency and for the company's leadership in the global plasma industry.

### **Grifols generates an unprecedented healthcare impact in Egypt**

Achieving self-sufficient access to plasma-derived medicines poses a technical, economic, and logistical challenge that few countries have been able to overcome. Without a network of donation centers, processing infrastructure, and a regulatory framework, dependence on external supplies becomes an unavoidable reality. This was the case in Egypt, where, according to United Nations data, reliance on third parties represented a tangible risk for the healthcare system of a country with more than 115 million inhabitants.

In 2020, the Egyptian Government and Grifols sealed a strategic alliance that today stands as an international benchmark. As a result of this agreement, Grifols Egypt for Plasma Derivatives (GEPD) was created, a public-private partnership project that has enabled the country to produce its own plasma-derived medicines and lay the foundations of a national industry built on sovereignty, knowledge transfer, and sustainable development.

Currently, Egypt collects enough plasma from voluntary donors to meet the internal demand for all the medicines supplied by GEPD. This structural advancement has transformed its healthcare system, expanding treatment options for patients with chronic or rare diseases and strengthening national capacity to diagnose, treat, and manage these conditions without relying on the international market.

Specifically, since the project started, more than 1,000,000 vials of essential medicines produced with Egyptian plasma have been delivered to Egypt. The system has also enabled more than 100,000 free medical check-ups for donors.

### **Grifols' healthcare self-sufficiency boosts the Egyptian economy**

This public-private healthcare alliance has already generated a profound economic impact. Grifols, through GEPD, will contribute 55 million euros to Egypt's GDP in 2025 alone, and it estimates that it will add more than 272 million euros yearly to the country's GDP by 2030. This estimate reflects the direct impact generated by GEPD's operations across its entire network of donation centers, fractionation plant, analytical laboratory, and logistics hub; the indirect impact linked to local suppliers and service providers supporting the project; and the induced impact resulting from consumer spending by households whose income comes from these direct and indirect jobs.

Specifically, during the growth plan between 2026 and 2029, GEPD will receive approximately 209 million euros in direct investments, and it expects these investments to generate significant direct, indirect, and induced effects. Altogether, the total economic impact on the country's GDP during this period is projected to exceed 700 million euros, combining all direct, indirect, and induced effects.

Grifols impact in Egypt is also social. With this project, Grifols, through GEPD, has already created 1,200 high-quality, highly skilled direct jobs, nearly 10,150 indirect jobs, and 4,200 induced jobs in the country. During the 2026–2029 growth plan, it is estimated that the country will see 186,000 new jobs, 44,700 of them direct, 107,800 indirect, and 34,280 induced.

Grifols has also created and launched the Grifols Academy for Plasmapheresis in Cairo, the first African institution dedicated to technical training in this field, where more than 170,000 hours of training have been delivered. The institution offers programs for all personnel—selected and trained by Grifols—under international standards, following a model that combines sustainability, scalability, and operational autonomy. This comprehensive and complementary training model has been designed to build in-country capabilities and prepare Egyptian workers to operate the system independently, without relying on foreign experts.

The launch of GEPD has also fostered training programs with Egyptian universities to educate specialized professionals who can integrate into GEPD's operational structure, consolidating a self-sufficient professional ecosystem free from dependence on foreign expertise. All of this is part of a broader vision that turns self-sufficiency into a driver of development based on education, skills transfer, and qualified employment, supported by a joint investment of 280 million euros to transform the system from within.

Grifols also collaborates with international organizations such as the World Federation of Hemophilia (WFH) and IPOPI on training programs and donations of coagulation factors, strengthening the country's clinical capacity. The cumulative social impact of the use of plasma-derived therapies is above 80 million euros in health benefits, reflected in more diagnoses, more treatments, and greater prevention.

### **A strategic project for the health sovereignty of Africa and the Middle East**

The plasma cycle is a highly specialized process that transforms a donation into essential medicines. It all begins with the extraction of plasma through plasmapheresis, a safe procedure that separates plasma from the other components of blood. The plasma then undergoes rigorous testing and fractionation and purification processes, during which its main therapeutic proteins are isolated: immunoglobulins, albumin, and coagulation factors.

Beyond achieving national self-sufficiency in these medicines, the project is also a strategic lever for the country. Once national needs are met, surplus plasma opens new commercial opportunities with neighbouring countries, fostering a model of regional self-sufficiency and healthcare cooperation that can extend to Africa, the Middle East and Europe.

Thus, thanks to GEPD's efforts, Egypt is emerging as a regional hub: its geopolitical position between Africa and the Middle East, combined with its new industrial capabilities, paves the way for it to become a regional supplier of plasma-derived medicines and a replicable model for other nations seeking to reduce their dependence on foreign suppliers.

Grifols Egypt recently strengthened this outlook through the appointment of Tomás Dagá as Vice President of the GEPD Board, a key figure in the company's international strategy. His official appointment, after leading the project's roadmap since 2020 and in line with his role within the current Grifols Strategy Committee, will accelerate industrial consolidation, regulatory compliance and the strategic relationship with the Egyptian authorities.

### **Plasma self-sufficiency is one of Grifols' strategic pillars**

Grifols drives projects that enable countries to produce their own plasma-derived medicines, reduce their dependence on external sources, and strengthen the resilience of their healthcare systems. With more than 115 years of experience, Grifols manages nearly 30% of the world's plasma and operates a network of more than 400 donation centers. Its vertically integrated model, spanning from donation to the production of the final medicine, ensures traceability, quality, and healthcare sovereignty, making it a benchmark for patients, health systems, and governments worldwide.

Through public-private partnerships such as those developed in Canada with Canadian Blood Services (CBS) or with the government of Egypt, Grifols helps build sustainable national networks for plasma collection and production that promote strategic autonomy, supply security, and equitable

access to essential therapies. All of this makes Grifols the only pharmaceutical company with the real capacity and proven experience to guarantee plasma self-sufficiency.

In a context of rising global demand for immunoglobulins and albumin, and increasing vulnerability in international supply chains, the company reaffirms its commitment to self-sufficiency as a driver of health, economic development, and industrial sovereignty.

## **MEDIA CONTACTS:**

### **Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## **About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

## **LEGAL DISCLAIMER**

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other*

*jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*